A Vaccine Against Group B : Recent Advances

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2020 May 20

PMID 32425562

Citations 50

Authors

Clara Carreras-Abad

Laxmee Ramkhelawon

Paul T Heath

Kirsty Le Doare

Affiliations

Soon will be listed here.

Abstract

Group B (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World Health Organisation (WHO). GBS serotype-specific polysaccharide - protein conjugate vaccines are at advanced stages of development, but a large number of participants would be required to undertake Phase III clinical efficacy trials. Efforts are therefore currently focused on establishing serocorrelates of protection in natural immunity studies as an alternative pathway for licensure of a GBS vaccine, followed by Phase IV studies to evaluate safety and effectiveness. Protein vaccines are in earlier stages of development but are highly promising as they might confer protection irrespective of serotype. Further epidemiological, immunological and health economic studies are required to enable the vaccine to reach its target population as soon as possible.

Citing Articles

Trends of neonatal sepsis and its etiology at Hawassa, Ethiopia: a five year retrospective cross-sectional study.

Ali M, Kwatra G, Mengistu M, Kijineh B, Hailemeriam T, Worku E BMC Pediatr. 2025; 25(1):152.

PMID: 40022032 PMC: 11869412. DOI: 10.1186/s12887-025-05515-w.

Perception of a Novel Group B Streptococcus Vaccine Among Pregnant and Lactating Individuals.

Sosa M, Haghighi C, Pike M, Stolarczuk J, Martinez-King C, Shree R Pediatr Infect Dis J. 2025; 44(2S):S149-S152.

PMID: 39951094 PMC: 11893083. DOI: 10.1097/INF.0000000000004641.

Pharmacovigilance for Vaccines Used in Pregnancy: A Gap Analysis From Uganda.

Nambasa V, Ssebagereka A, Ssali A, Namugumya R, Nalubega P, Figueras A Pediatr Infect Dis J. 2025; 44(2S):S123-S129.

PMID: 39951089 PMC: 7617404. DOI: 10.1097/INF.0000000000004705.

The challenge of antimicrobial resistance in the Asia-Pacific: a pediatric perspective.

Huong N, Harrison M, Kasahara E, Marais B, Putri N, Williams P Curr Opin Pediatr. 2025; 37(2):116-123.

PMID: 39882689 PMC: 11892997. DOI: 10.1097/MOP.0000000000001437.

Gathering information on maternal immunization readiness in Bangladesh, Ghana, Kenya, Mozambique, and Nepal: Applying a WHO checklist.

Baral R, Knudson S, Barros I, Cofie P, Dapaah P, Khan S Hum Vaccin Immunother. 2024; 20(1):2437258.

PMID: 39687966 PMC: 11654705. DOI: 10.1080/21645515.2024.2437258.

References

Madhi S, Cutland C, Kuwanda L, Weinberg A, Hugo A, Jones S . Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014; 371(10):918-31. DOI: 10.1056/NEJMoa1401480. View

Baker C, Rench M, McInnes P . Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003; 21(24):3468-72. DOI: 10.1016/s0264-410x(03)00353-0. View

Kobayashi M, Schrag S, Alderson M, Madhi S, Baker C, Sobanjo-Ter Meulen A . WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016. Vaccine. 2016; 37(50):7307-7314. PMC: 6892266. DOI: 10.1016/j.vaccine.2016.12.029. View

Kim S, Russell L, Park J, Verani J, Madhi S, Cutland C . Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014; 32(17):1954-63. DOI: 10.1016/j.vaccine.2014.01.062. View

Le Doare K, Kampmann B, Vekemans J, Heath P, Goldblatt D, Nahm M . Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019; 19(5):e162-e171. DOI: 10.1016/S1473-3099(18)30659-5. View

Herbert M, Beveridge C, Saunders N . Bacterial virulence factors in neonatal sepsis: group B streptococcus. Curr Opin Infect Dis. 2004; 17(3):225-9. DOI: 10.1097/00001432-200406000-00009. View

Slotved H, Kong F, Lambertsen L, Sauer S, Gilbert G . Serotype IX, a Proposed New Streptococcus agalactiae Serotype. J Clin Microbiol. 2007; 45(9):2929-36. PMC: 2045254. DOI: 10.1128/JCM.00117-07. View

Lin F, Philips 3rd J, Azimi P, Weisman L, Clark P, Rhoads G . Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis. 2001; 184(8):1022-8. DOI: 10.1086/323350. View

Ferrieri P, Lynfield R, Creti R, Flores A . Serotype IV and invasive group B Streptococcus disease in neonates, Minnesota, USA, 2000-2010. Emerg Infect Dis. 2013; 19(4):551-8. PMC: 3647718. DOI: 10.3201/eid1904.121572. View

10.

Carreras-Abad C, Cochet M, Hall T, Ramkhelawon L, Khalil A, Peregrine E . Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study. Health Technol Assess. 2019; 23(67):1-40. PMC: 6936166. DOI: 10.3310/hta23670. View

11.

Vekemans J, Moorthy V, Friede M, Alderson M, Sobanjo-Ter Meulen A, Baker C . Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2018; 37(50):7391-7393. PMC: 6892248. DOI: 10.1016/j.vaccine.2017.09.087. View

12.

Martins E, Pessanha M, Ramirez M, Melo-Cristino J . Analysis of group B streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with enhanced invasiveness. J Clin Microbiol. 2007; 45(10):3224-9. PMC: 2045366. DOI: 10.1128/JCM.01182-07. View

13.

Fabbrini M, Rigat F, Tuscano G, Chiarot E, Donders G, Devlieger R . Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. J Infect. 2018; 76(5):449-456. DOI: 10.1016/j.jinf.2018.01.006. View

14.

Le Doare K, Faal A, Jaiteh M, Sarfo F, Taylor S, Warburton F . Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort. Vaccine. 2017; 35(22):2970-2978. PMC: 5432431. DOI: 10.1016/j.vaccine.2017.04.013. View

15.

Boldenow E, Gendrin C, Ngo L, Bierle C, Vornhagen J, Coleman M . Group B Streptococcus circumvents neutrophils and neutrophil extracellular traps during amniotic cavity invasion and preterm labor. Sci Immunol. 2016; 1(4). PMC: 5089172. DOI: 10.1126/sciimmunol.aah4576. View

16.

Pavliakova D, Giardina P, Moghazeh S, Sebastian S, Koster M, Pavliak V . Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Capsular Polysaccharides. mSphere. 2018; 3(4). PMC: 6083093. DOI: 10.1128/mSphere.00128-18. View

17.

Baker C, Kasper D . Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976; 294(14):753-6. DOI: 10.1056/NEJM197604012941404. View

18.

Leroux-Roels G, Maes C, Willekens J, De Boever F, de Rooij R, Martell L . A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine. 2016; 34(15):1786-91. DOI: 10.1016/j.vaccine.2016.02.044. View

19.

Sigauque B, Kobayashi M, Vubil D, Nhacolo A, Chauque A, Moaine B . Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001-2015. PLoS One. 2018; 13(1):e0191193. PMC: 5774717. DOI: 10.1371/journal.pone.0191193. View

20.

Madhi S, Dangor Z, Heath P, Schrag S, Izu A, Sobanjo-Ter Meulen A . Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 2013; 31 Suppl 4:D52-7. DOI: 10.1016/j.vaccine.2013.02.029. View